Novo Nordisk, one of the principal suppliers of GLP-1 weight-loss medication, has handed a board role to the chief executive of Mars. Poul Weihrauch is to be a “board observer” at the pharma group, which markets GLP-1 drugs under brands including Ozempic and Wegovy. GLP-1 medication, associated with appetite suppression, was first approved to treat Type-2 diabetes in the US more than 15 years ago and for the treatment of obesity around a decade ago. However, with more consumers turning to the drugs to ...

Novo Nordisk A/S (NYSE:NVO) is one of Jim Cramer’s Hottest GLP-1 and Weight Loss Stock Picks. Novo Nordisk A/S (NYSE:NVO) is a key player in the weight loss drug industry. The firm made a splash earlier this year when it became the first to secure the FDA’s approval for a weight loss drug pill. With the announcement occurring on December 22nd, Novo Nordisk A/S (NYSE:NVO)’s shares closed 7.3% higher on the 23rd. Since Cramer discussed the firm in April 2025, the shares are up by 44%, while they are down by ...

整理 | GLP1减重宝典内容团队 市场最近盯上的，正是礼来的口服GLP-1药物 orforglipron。更准确地说，它不是已经确定会在4月正式开卖，而是审批窗口已经逼近。 礼来自己的公开表述是，这款药针对肥胖或超重适应症的美国监管结果有望在2026年第二季度出炉，市场普遍关注的时间点集中在4月 上旬。礼来管理层同时表示，公司正按二季度上市的节奏做准备。 如果这张牌顺利落地，最先感到疼的，不会是整个司美格鲁肽市场同时被掀翻，而是口服司美格鲁肽先被正面撞上。礼来披露， orforglipron 是一款每日一次的小分子口服GLP-1，可以不受进食和饮水限制服用；相比之下，诺和诺德现有的 Rybelsus 和 Wegovy 片 剂都要求晨起空腹、以少量清水送服，并至少等待30分钟后才能进食、饮水或服用其他口服药。对真实世界依从性来说，这不是小差 别，而是会直接影响患者能不能长期坚持。 数据层面，礼来也已经把矛头直接对准了口服司美格鲁肽。在一项头对头Ⅲ期研究中，orforglipron 36 mg 在2型糖尿病患者中的糖化血 红蛋白降幅达到2.2%，口服司美格鲁肽14 mg为1.4%；体重降幅分别为9.2%和5.3 ...

整理 | GLP1减重宝典内容团队 当地时间3月26日，诺和诺德在年度股东大会上宣布，任命玛氏公司首席执行官波尔·魏拉赫为董事会观察员，任期覆盖2026至2027年 度，并计划在2027年年度股东大会上提名其正式进入董事会。这一安排看似只是常规董事会更新，但在全球减肥药竞争格局快速变化的 当下，这更像是诺和诺德对下一阶段竞争方向的一次提前落子。公司公开释放的信号已经很明确，肥胖症治疗市场正在变得越来越消费 者驱动，诺和诺德需要的不只是药物研发和生产能力，还需要更强的消费者洞察、品牌运营和渠道理解能力。 过去几年，诺和诺德依靠司美格鲁肽类产品建立起减重药市场的先发优势，Wegovy一度成为全球减肥药浪潮中最具代表性的产品之 一。但到了2026年，这个市场的游戏规则已经发生变化。竞争不再只是围绕临床数据、供应能力和医保覆盖展开，而是逐步延伸到价格 策略、现金支付、自费患者教育、零售触达、远程医疗合作以及用户长期依从性管理。在这样的背景下，引入一位长期浸泡在全球消费 品行业的高管，逻辑就变得十分清晰。 从某种意义上说，诺和诺德这次补的不是医药能力，而是消费能力。减肥药在全球市场尤其是美国市场，正在从一种高度专业化的 ...

整理 | GLP1减重宝典内容团队 3月27日，诺和诺德宣布，美国食品药品监督管理局已批准Awiqli®（依柯胰岛素注射液，700单位/毫升）上市，用于作为饮食和运动的辅助手 段，改善成人2型糖尿病患者的血糖控制。该药物也成为美国首款且目前唯一一款每周一次给药的长效基础胰岛素。 此次获批的意义，不在于这款产品第一次在全球上市，而在于它终于拿下了美国市场。Awiqli此前已在中国获批用于成人2型糖尿病，也已在加 拿大、瑞士等海外市场获批。 FDA此次批准，基于ONWARDS 3a期临床项目结果。该项目围绕每周一次Awiqli用于2型糖尿病治疗展开，包含4项随机、活性对照、目标治疗 试验，共纳入约2680例血糖控制不佳的成人2型糖尿病患者。研究中，Awiqli与餐时胰岛素联用，或与常用口服降糖药和/或GLP-1受体激动剂 联用。 从结果来看，Awiqli在关键临床试验中达到了降低糖化血红蛋白这一主要终点，整体安全性特征与每日基础胰岛素类别总体一致。对患者而 言，这款产品最大的变化，是把原本每周7次的基础胰岛素注射，减少为每周1次，为需要长期胰岛素治疗的2型糖尿病患者提供了新的治疗选 择。 *本文仅供医疗卫生专业人 ...

Key Takeaways Novo Nordisk won FDA approval for Awiqli, a once-weekly basal insulin for adults with type II diabetes.Awiqli showed strong HbA1c reduction in the phase IIIa ONWARDS studies vs. daily basal insulin.NVO plans a U.S. launch of the FlexTouch device in the second half of 2026 after global approvals.Novo Nordisk (NVO) announced that the FDA has approved Awiqli injection as the first and only once-weekly, long-acting basal insulin icodec for adults with type II diabetes (T2D). The therapy is indicat ...

Over the past year, the two leaders in the obesity drug market, Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), have lagged broader equities, though the latter has performed substantially worse than the former. Still, analysts predict that this therapeutic area will soar over the next decade, and there is a good chance these two will maintain their edge over their peers given their pipelines. But which one is a better buy? Comparing their weight loss portfolios Eli Lilly's weight loss medicine, Zepbou ...

Conventional wisdom increasingly frames Novo Nordisk A/S ( NVO ) as the loser in its battle with Eli Lilly and Company ( LLY ) for the obesity drug market. I think that’s wrong. The analogy here isn’t Netflix versus Blockbuster, where oneThe Edson Spencer Professor of Strategy and Technological Leadership at the University of Minnesota Carlson School of Management Alfred Marcus' most recent book, Comeback: Can Great Companies Rise Again is available on Amazon. He is host of the popular New Books Network Pod ...

Articles of Association for Novo Nordisk A/S 2026 Attachment AOA260326-NN Articles of Association 2026 ...

FDA has approved Awiqli® injection 700 units/mL, the first and only once-weekly, long-acting basal insulin as an adjunct to diet and exercise to improve .. Read More ...